INTERVET INTERNATIONAL BV

Their core work

Intervet International (operating as part of MSD Animal Health / Merck Animal Health) is a major veterinary pharmaceutical company headquartered in Boxmeer, Netherlands, specializing in animal vaccine development and manufacturing. Within H2020, they contribute industrial-scale vaccine expertise to consortia tackling infectious animal diseases — from engineered mycoplasma-based vaccines to African Swine Fever control. Their role is that of a large pharma partner bringing manufacturing capacity, quality control know-how, and regulatory experience to academic-led research projects.

What they specialise in

How they've shifted over time

In the earlier period (2015–2017), Intervet engaged in forward-looking vaccine platform work — synthetic biology-based vaccine engineering (MycoSynVac) and vaccine manufacturing quality standards (VAC2VAC). By 2019, their focus shifted toward urgent applied challenges, specifically African Swine Fever vaccine development and the DIVA diagnostic approach (VACDIVA). This evolution mirrors the broader European livestock industry's pivot toward ASF as the disease spread westward across Europe.

Intervet is moving from foundational vaccine science toward urgent livestock disease response, suggesting they are positioning for applied ASF vaccine commercialization.

How they like to work

Intervet participates exclusively as a consortium partner — never as coordinator — which is typical for large pharma companies contributing industrial expertise to academic-led research. With 63 unique partners across 19 countries from just 4 projects, they operate in large, diverse consortia. Their role is to bring manufacturing scale, regulatory knowledge, and commercial pathway expertise rather than to drive research direction.

Across 4 projects, Intervet has worked with 63 unique partners in 19 countries — an exceptionally broad network for a small project portfolio, reflecting participation in large EU consortia spanning veterinary science, biology, and public health institutions across Europe.

What sets them apart

Intervet is one of the world's largest animal health companies (part of MSD/Merck), which means they bring something most academic consortia lack: a direct path from research to commercial vaccine production and global distribution. Their participation signals serious commercialization intent — if Intervet is in your consortium, the vaccine has a realistic route to market. For consortium builders, they offer industrial-grade vaccine manufacturing and regulatory expertise that is difficult to find elsewhere.

Highlights from their portfolio

• MycoSynVac
  Largest funding share (EUR 1.48M) and an ambitious synthetic biology approach to engineering a broad-spectrum animal vaccine from Mycoplasma pneumoniae.
• VACDIVA
  Addresses African Swine Fever — one of the most economically devastating livestock diseases in Europe — with a DIVA vaccine enabling differentiation of infected from vaccinated animals.